FKRCX
Price
$49.29
Change
+$0.57 (+1.17%)
Updated
Jun 2 closing price
Net Assets
3.4B
MIDSX
Price
$3.69
Change
+$0.01 (+0.27%)
Updated
Jun 2 closing price
Net Assets
42.24M
Interact to see
Advertisement

FKRCX vs MIDSX

Header iconFKRCX vs MIDSX Comparison
Open Charts FKRCX vs MIDSXBanner chart's image
FKRCX vs MIDSX Comparison Chart in %
View a ticker or compare two or three
VS
FKRCX vs. MIDSX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FKRCX is a Buy and MIDSX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FKRCX has more cash in the bank: 3.4B vs. MIDSX (42.2M). FKRCX pays higher dividends than MIDSX: FKRCX (9.93) vs MIDSX (0.00). FKRCX was incepted earlier than MIDSX: FKRCX (57 years) vs MIDSX (40 years). MIDSX (3.47) is less costly to investors than FKRCX (0.87). MIDSX is a more actively managed with annual turnover of: 28.00 vs. FKRCX (22.76). FKRCX (1000) and MIDSX (1000) have matching initial minimum investment requirements. FKRCX annual gain was more profitable for investors over the last year : 85.11 vs. MIDSX (71.96). FKRCX return over 5 years is better than : 164.31 vs. MIDSX (132.91).
FKRCXMIDSXFKRCX / MIDSX
Total Expense Ratio0.873.4725%
Annual Report Gross Expense Ratio0.873.4725%
Fund Existence57 years40 years-
Gain YTD5.5925.444103%
Front Load6%N/A-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets3.4B42.2M8,055%
Annual Yield % from dividends9.930.00-
Returns for 1 year85.1171.96118%
Returns for 3 years259.64206.67126%
Returns for 5 years164.31132.91124%
Returns for 10 years330.15187.50176%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EDSA6.830.14
+2.09%
Edesa Biotech
LANDP20.40-0.03
-0.15%
Gladstone Land Corp
SIRI28.77-0.27
-0.93%
SiriusXM Holdings Inc
DUOT13.81-0.43
-3.02%
Duos Technologies Group
NTLA13.13-0.60
-4.37%
Intellia Therapeutics